<?xml version="1.0" encoding="UTF-8"?>
<p>Many protozoan diseases are endemic in tropical countries, affecting millions of humans and animals, and causing serious economic losses annually, especially to developing economies. Most of these parasitic diseases attract little attention with regard to the development of new drugs, mainly because of poor profitability prospects. In addition, the development of resistance by these parasites to nearly all currently used chemotherapies, in addition to toxicity issues and the increasing cost of unrelated drugs, has led to an ever-increasing need to explore cheaper, accessible sources of safe new antiprotozoal agents (de Koning, 
 <xref rid="B33" ref-type="bibr">2017</xref>).
</p>
